Form 4: Tvardi Therapeutics CFO Acquires Stock Options
SEC Form 4 Filing
Avi Daniel Conn, CFO of Tvardi Therapeutics, acquires 43,547 employee stock options at an exercise price of $17.04.
Summary
- On April 17, 2025, Avi Daniel Conn, the Chief Financial Officer of Tvardi Therapeutics, acquired 43,547 employee stock options.
- The exercise price of these options is $17.04.
- The options vest over time, with 25% vesting on April 17, 2026, and the remaining balance vesting in equal monthly installments over the subsequent 36 months, contingent upon continuous service.
- The options expire on April 16, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for company executives to receive stock options as part of their compensation packages.
Stakeholder Impact
- The granting of stock options aligns the CFO's interests with those of the shareholders, incentivizing him to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 04/17/2025 | Date of transaction: CFO acquired employee stock options. |
| 04/17/2026 | 25% of the acquired stock options vest. |
| 04/16/2035 | Expiration date of the acquired stock options. |
| 04/21/2025 | Date of Form 4 filing. |
Keywords
Tvardi Therapeutics, stock options, Form 4, Avi Daniel Conn, CFO, beneficial ownership, equity securities, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.